Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain

Mazagatos, Clara; Mendioroz, Jacobo; Rumayor, Mercedes-Belén; Gallardo-García, Virtudes; Álvarez-Rio, Virginia; Gracia, Ana-Delia-Cebollada; Rebollo, Noa-Batalla; Barranco-Boada, María-Isabel; Pérez-Martínez, Olaia; Lameiras-Azevedo, Ana-Sofía; López-González-Coviella, Nieves; Castrillejo, Daniel; Ibáñez, Ana-Fernández; Giménez-Durán, Jaume; Ramírez-Córcoles, Cristina; Ramos-Marín, Violeta; Larrauri, Amparo; Monge, Susana

RICSMUR Principal
→
03. IMIB (Instituto Murciano de Investigación Biosanitaria Pascual Parrilla)
→
03.01. Investigación y comunicación científica
→
Ver ítem

dc.contributor.author	Mazagatos, Clara
dc.contributor.author	Mendioroz, Jacobo
dc.contributor.author	Rumayor, Mercedes-Belén
dc.contributor.author	Gallardo-García, Virtudes
dc.contributor.author	Álvarez-Rio, Virginia
dc.contributor.author	Gracia, Ana-Delia-Cebollada
dc.contributor.author	Rebollo, Noa-Batalla
dc.contributor.author	Barranco-Boada, María-Isabel
dc.contributor.author	Pérez-Martínez, Olaia
dc.contributor.author	Lameiras-Azevedo, Ana-Sofía
dc.contributor.author	López-González-Coviella, Nieves
dc.contributor.author	Castrillejo, Daniel
dc.contributor.author	Ibáñez, Ana-Fernández
dc.contributor.author	Giménez-Durán, Jaume
dc.contributor.author	Ramírez-Córcoles, Cristina
dc.contributor.author	Ramos-Marín, Violeta
dc.contributor.author	Larrauri, Amparo
dc.contributor.author	Monge, Susana
dc.date.accessioned	2025-11-20T07:25:27Z
dc.date.available	2025-11-20T07:25:27Z
dc.date.issued	2024-05
dc.identifier.citation	Mazagatos C, Mendioroz J, Rumayor MB, Gallardo García V, Álvarez Río V, Cebollada Gracia AD, et al. Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain. Influenza Resp Viruses. mayo de 2024;18(5):e13294.
dc.identifier.issn	1750-2640
dc.identifier.uri	https://sms.carm.es/ricsmur/handle/123456789/21585
dc.description.abstract	BACKGROUND: Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards. METHODS: Estimated RSV hospitalisations in < 1-year-olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23. RESULTS: We estimated 9364-9875 RSV hospitalisations less than expected, corresponding to a 74%-75% reduction.
dc.language.iso	eng
dc.publisher	WILEY
dc.rights	http://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.rights.uri	Atribución-NoComercial-SinDerivadas 3.0 España	*
dc.subject.mesh	Humans
dc.subject.mesh	Respiratory Syncytial Virus Infections/epidemiology/drug therapy
dc.subject.mesh	Spain/epidemiology
dc.subject.mesh	Infant
dc.subject.mesh	Hospitalization/statistics & numerical data
dc.subject.mesh	Incidence
dc.subject.mesh	Antiviral Agents/therapeutic use
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	Respiratory Syncytial Virus, Human
dc.subject.mesh	Sentinel Surveillance
dc.subject.mesh	Infant, Newborn
dc.subject.mesh	Antibodies, Monoclonal, Humanized/therapeutic use
dc.title	Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain
dc.type	info:eu-repo/semantics/article
dc.identifier.pmid	38716791
dc.relation.publisherversion	https://onlinelibrary.wiley.com/doi/10.1111/irv.13294
dc.identifier.doi	10.1111/irv.13294
dc.journal.title	Influenza and Other Respiratory Viruses
dc.identifier.essn	1750-2659